Last reviewed · How we verify
Zaldiar®
Zaldiar combines tramadol (an opioid agonist and monoamine reuptake inhibitor) with paracetamol (acetaminophen) to provide analgesia through dual pathways.
Zaldiar combines tramadol (an opioid agonist and monoamine reuptake inhibitor) with paracetamol (acetaminophen) to provide analgesia through dual pathways. Used for Moderate acute pain, Moderate chronic pain.
At a glance
| Generic name | Zaldiar® |
|---|---|
| Also known as | Oral Zaldiar |
| Sponsor | Labopharm Inc. |
| Drug class | Opioid analgesic combination |
| Target | μ-opioid receptor; norepinephrine and serotonin transporters; COX (paracetamol component) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Tramadol acts as a weak μ-opioid receptor agonist and inhibits the reuptake of norepinephrine and serotonin, enhancing descending pain inhibitory pathways. Paracetamol works through poorly understood mechanisms involving central COX inhibition and endocannabinoid system modulation. The combination provides synergistic pain relief for moderate pain.
Approved indications
- Moderate acute pain
- Moderate chronic pain
Common side effects
- Nausea
- Dizziness
- Constipation
- Headache
- Somnolence
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |